Quantcast

Latest Placebo-controlled study Stories

2014-05-15 08:31:10

TORONTO, May 15, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient in a Phase 2 clinical study of TT-401 (LY2944876), a drug candidate for the treatment of type 2 diabetes. The study is expected to enroll up to 375 type 2 diabetes subjects and will be performed by Transition's development partner, Eli Lilly and Company ("Lilly"). The objectives of the study will be to...

2014-05-06 08:36:03

CLEVELAND, May 6, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking oral presentation at the European Society of Cardiology Heart Failure Congress (ESC-HF) taking place May 17 - 20, 2014 in Athens, Greece. The STOP-HF trial is a randomized, placebo-controlled, double-blinded study conducted at 15 centers in the United States to evaluate safety and efficacy of...

2014-05-06 08:33:30

TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. This sNDA application was granted Priority Review...

2014-05-01 04:22:31

Can a Simple Pill Truly Reshape Your Body in 30 Days? SAN DIEGO, May 1, 2014 /PRNewswire/ -- When people walked into the huge exhibit hall for the Experimental Biology conference that ended yesterday at the San Diego Convention Center, their eye was immediately drawn to one thing: the crowd standing under a provocative banner that read: "Reshape Your Entire Body in 30 Days?" The banner referred to a "body-reshaping" pill called Vysera(TM)-CLS. Why were biology experts so interested...

2014-04-30 08:34:12

LEXINGTON, Massachusetts, April 30, 2014 /PRNewswire/ -- - OPUS-2, a Phase 3 placebo-controlled study of lifitegrast 5.0%; results presented at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston - SONATA, a Phase 3 placebo-controlled, long-term (one-year) safety study of lifitegrast 5.0%; top-line results announced Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty...

2014-04-16 00:21:06

TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American...

2014-04-11 00:21:52

-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic hepatitis C virus infection LONDON, April 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress(TM) (ILC) 2014 and featured in the ILC press conference....

2014-03-11 23:33:04

Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus erythematosus (SLE). Birmingham, Alabama (PRWEB) March 11, 2014 *To see if you qualify for this Lupus Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no...

2014-02-25 08:31:00

- Study Meets Primary and Both Key Secondary Endpoints - BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), demonstrated that pirfenidone significantly reduced IPF disease progression as measured by change in percent predicted forced vital capacity (FVC) from Baseline to Week 52 (rank ANCOVA p<0.000001)....

2014-02-13 23:26:10

RE-BODY® Launches RE-BODY Fruit & Flower Slimming Formula™ with Meratrim® Gainesville, Fla (PRWEB) February 13, 2014 RE-BODY®, a market leader in healthy weight management supplements, has launched RE-BODY Fruit & Flower Slimming Formula™ with Meratrim®, the newest addition to the brand’s already dynamic product line. RE-BODY Fruit & Flower Slimming Formula is non-stimulant and features pure Meratrim, a blend of plant extracts derived from...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.